Ozempic®, Wegovy® and Mounjaro®: differences in diabetes and weight management

Three medications, two different active ingredients

Ozempic® and Wegovy® contain semaglutide. Mounjaro® contains tirzepatide.

Semaglutide acts on GLP-1 receptors, which are involved in regulating blood sugar and appetite. Tirzepatide acts on two types of receptors: GLP-1 and GIP.

These medications are not insulin. They help the pancreas release insulin when blood sugar rises, among other effects. The injectable forms discussed here are administered once a week.

Ozempic®: a treatment for type 2 diabetes

Ozempic® is approved in the US to improve blood sugar control in adults with type 2 diabetes, alongside diet and physical activity.

It may be prescribed alone or with other diabetes medications, depending on the person’s treatment needs.

Weight loss may also occur, but Ozempic® is not approved specifically for weight management. It is important to distinguish a possible effect of a medication from the condition it is approved to treat.

Ozempic® also has approved uses for reducing certain cardiovascular risks in adults with type 2 diabetes and established cardiovascular disease, and certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.

Wegovy®: a treatment for weight management

Wegovy® contains semaglutide, like Ozempic®, but its weight-management indication is different.

For weight management in adults, it is used alongside a reduced-calorie eating plan and increased physical activity in people with:

• A BMI of 30 kg/m² or higher;
• A BMI of 27 kg/m² or higher with at least one weight-related health condition.

Type 2 diabetes can be one of these associated conditions. Someone with diabetes may therefore receive Wegovy® for weight management if they meet the criteria. This does not make it a medication specifically approved to manage blood sugar in type 2 diabetes.

Wegovy® also has additional US indications, including cardiovascular risk reduction in eligible adults. Its injectable form is approved for certain adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis, without cirrhosis.

Doses and prescribing instructions differ from those for Ozempic®. Sharing an active ingredient does not mean that you can switch products yourself.

Mounjaro®: a dual action for type 2 diabetes

Mounjaro® acts on both GIP and GLP-1 receptors. This dual action contributes to blood sugar control and reduced appetite.

In the US, Mounjaro® is approved to improve blood sugar control in people with type 2 diabetes, alongside diet and physical activity. It also has an indication for reducing major cardiovascular events in adults with type 2 diabetes who are at high risk.

Mounjaro® is not the US brand approved for weight management. Tirzepatide is marketed for that purpose as Zepbound®.

Although Mounjaro® and Zepbound® contain the same active ingredient, their approved uses and prescribing information differ. A change between products requires a prescribing decision.

The main differences to understand

The first difference is the active ingredient: Ozempic® and Wegovy® contain semaglutide, while Mounjaro® contains tirzepatide.

The second is how they work. Semaglutide targets GLP-1 receptors, whereas tirzepatide targets both GLP-1 and GIP receptors.

The third is their approved use. For the purposes of this comparison, Ozempic® and Mounjaro® are diabetes treatments, while Wegovy® is a weight-management treatment. Some also have additional approved uses in specific patient groups.

Finally, FDA approval and insurance coverage are separate matters. A medication may be approved for a particular condition without being covered by every insurance plan.

What side effects and precautions should you know about?

The most common side effects involve digestion: nausea, diarrhea, vomiting and, depending on the medication, constipation or abdominal pain. These may occur particularly when treatment begins or the dose increases.

The risk of low blood sugar, or hypoglycemia, needs particular attention when one of these treatments is combined with insulin or a sulfonylurea. The prescriber may need to adjust the accompanying medication.

Severe, persistent abdominal pain requires urgent medical advice, including assessment for pancreatitis. Repeated vomiting can also lead to dehydration.

All three medications carry US boxed warnings about thyroid C-cell tumors observed in rodents. Whether they cause these tumors in humans is unknown. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).

Pregnancy plans and contraception should also be discussed with the prescriber. Tirzepatide can affect the reliability of oral hormonal contraceptives when treatment starts and after dose increases.

Tell your doctor or pharmacist about any troublesome or persistent side effects so they can advise you on what to do.

Choosing treatment means considering your whole situation

Choosing a treatment involves more than comparing its effect on weight.

For type 2 diabetes, the healthcare professional considers blood sugar control, current medications, other health conditions, tolerability and the goals agreed with the patient. Follow-up appointments help assess both benefits and difficulties.

Weight loss alone does not show whether diabetes is well controlled. Blood glucose readings and A1C remain important measures.

Nutrition, appropriate physical activity and ongoing support are also part of care. If injections, digestive side effects or treatment demands become difficult to manage, discuss them with your care team rather than changing doses or stopping treatment yourself.

The aim is to find a treatment that is effective, manageable and suited to daily life.

Key takeaways

Ozempic® and Mounjaro® treat type 2 diabetes, while Wegovy® is used for weight management in eligible patients. In the US, tirzepatide for weight management is sold as Zepbound®.

Even when medications share an ingredient or have similar effects, they are not interchangeable without a medical decision. Prescribing and treatment changes require an individual assessment.

Did you find this article helpful?

Click Like or share your thoughts and questions with the community in the comments below!

Take care of yourself!